Aparna Anderson, Ph.D., joined Statistics Collaborative, Inc. (SCI) in 2016 as Vice President and Chief Operating Officer, and in 2020 she became Chief Scientific Officer. She has extensive experience as a clinical trialist across a range of therapeutic areas. Prior to joining SCI, she worked at Bristol-Myers Squibb Company (BMS) from 1997 to 2016 and was an Assistant Professor in the Division of Biostatistics at the University of Minnesota from 1995 to 1997. She serves on the Executive Committee At Large for the American Statistical Association Section on Statistical Consulting for 2020-2022.
For more than twenty years, Dr. Anderson has contributed to clinical trial design, interpretation of trial results, conference presentations and manuscripts, diagnostic development, and health authority interactions. She has brought statistical and scientific perspectives to pipeline strategy, including proof-of-concept transition product development, due diligence for in-licensing and acquisitions, go/no-go decision-making, and Phase 3 trial design. She has interacted with regulators (e.g., FDA, EMA, and Health Canada) for end-of-Phase 2 and development discussions, pre- and post-submission meetings, and advisory committee presentations.
During her tenure at BMS, Dr. Anderson provided statistical leadership for the clinical development of ipilimumab and nivolumab, two pioneering therapies in the field of immuno-oncology. Her contributions to the ipilimumab melanoma trial designs resulted in global approvals for first- and second-line metastatic melanoma as well as adjuvant melanoma. During this period, she also collaborated with an interdisciplinary team of scientists in the first effort to define alternative response criteria to address response kinetics unique to immuno-oncology agents. For her contributions as the lead nivolumab statistician between 2011 and 2016, BMS recognized Dr. Anderson in 2016 with the James B. D. Palmer Award for Excellence in Drug Development.
Dr. Anderson has contributed to clinical development in numerous therapeutic areas in addition to oncology including rare diseases, neuroscience, pediatric indications, metabolic diseases, infectious diseases, and cardiovascular diseases. She has developed statistical analysis plans and data set submission plans for study-level and integrated analyses, and she has contributed to clinical components of Common Technical Documents. She also sits on multiple data monitoring committees (DMCs) to provide patient safety monitoring and interpretation of interim efficacy analyses in clinical studies.
While at the University of Minnesota, she taught courses in multiple linear regression and longitudinal data analysis, collaborated in grant submissions at the Center on Aging, and was part of an advisory panel for violence prevention grant-based research.
Dr. Anderson received a B.S. in Applied Mathematics from the University of California, Davis (1989) and her M.S. and Ph.D. in Biostatistics from the University of Washington (1995). In 1989-1990, she spent a year studying mathematics as a Fulbright scholar at the University of Göttingen, Federal Republic of Germany.
To contact SCI about a potential project, please call us at 202.247.9700 or click below.
Statistics Collaborative is experencing a business interruption due to circumstances beyond our control. Please call our main company phone number for details and updates.